Recent translational studies have also shown that Aβ-mediated impairment of LTP can be attenuated by co-treatment with the mGluR5 antagonist, MPEP (Wang et al., 2004; Rammes et al., 2011), suggesting mGluR5 may be an efficacious target for the treatment of AD. The gene discussed is GRM5; the disease is Alzheimer disease.